-
Regenxbio Charts Course for 2026: A Deep Dive into Duchenne Gene Therapy Milestones and Promising Long-Term Data
Biotechnology is often a story of patience, rigorous science, and the relentless pursuit of life-changing therapies. Nowhere is this more evident than in the field of gene therapy, especially concerning devastating conditions like Duchenne Muscular Dystrophy (DMD). Regenxbio, Inc. (NASDAQ: RGNX) has recently provided a significant update, illuminating a clear roadmap toward crucial 2026 catalysts…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
Sarepta Therapeutics (NasdaqGS:SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and their families, Sarepta…